The field force: Is small beautiful?
As big pharma ponders the right sizing of its post-pandemic field forces, can it learn from smaller, leaner industry peers about doing more with less?
Close log in window
Now that CGT is proving its worth, the next task for pharma is working out the best ways to commercialise it
The future looks bright for biosimilars in an age of crisis over healthcare affordability
To build on the successes thus far in cell and gene therapy, pharma must foster further payer, physician and patient buy-in
The events of 2020 have compelled pharma to reimagine the role of the rep to better adapt to the new rules of engagement
